Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | HTR1A | P08908 | 5/20 | 0.48 |
| ▸ | HTR1D | P28221 | 5/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 3/20 | 0.45 |
| ▸ | DRD4 | P21917 | 3/20 | 0.45 |
| ▸ | DRD3 | P35462 | 3/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | DRD5 | P21918 | 1/20 | 0.45 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1380267 | 0.86 | MTNR1A (0.62) | CA2HTR1AHTR1DMTNR1ADRD2 | |
| SCHEMBL1385775 | 0.86 | MTNR1A (0.62) | CA2HTR1AHTR1DMTNR1ADRD2 | |
| SCHEMBL1380270 | 0.86 | MTNR1A (0.62) | CA2HTR1AHTR1DMTNR1ADRD2 | |
| SCHEMBL1567983 | 0.85 | CA2 (0.60) | CA2HTR1AHTR1DMTNR1ADRD2 | |
| SCHEMBL4935025 | 0.85 | CA2 (0.60) | CA2HTR1AHTR1DDRD2DRD4 | |
| SCHEMBL23195321 | 0.82 | CA2 (0.58) | CA2HTR1AHTR1DDRD2DRD4 | |
| SCHEMBL30152355 | 0.82 | CA2 (0.58) | CA2HTR1AHTR1DDRD2DRD4 | |
| Cycloheptane SCHEMBL8317003 | 0.82 | CA2 (0.58) | CA2HTR1AHTR1DDRD2DRD4 | |
| Cyclopropane SCHEMBL6954169 | 0.82 | CA2 (0.58) | CA2HTR1AHTR1DDRD2DRD4 | |
| SCHEMBL6955676 | 0.82 | CA2 (0.58) | CA2HTR1AHTR1DMTNR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859584-B2 | TRPV1 antagonists | ABBVIE, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-20130158067-A1 | TRPV1 Antagonists | ABBVIE INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158067-A1 | TRPV1 Antagonists | TRPV1, NPY1R, MRGPRX1 | CA2 650/4885HTR1A 133/4885HTR1D 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.